Simponi, a subcutaneously administered anti-tumor necrosis factor therapy, has shown to induce clinical remission in ulcerative colitis patients.
More Articles on Gastroenterology:
PENTAX Launches Video Processor With PENTAX i-SCAN
SAGES Appoints Dr. Gerald Fried President
AGA Receives $1.5M Research Grant From Takeda Pharmaceuticals
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
